Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application

Bone Marrow Transplantation volume 55, pages 40–47 (2020)Cite this article

Subjects

Abstract

The last decade had witnessed a remarkable reduction in the incidence of acute and chronic GvHD (graft versus host disease) in both related and unrelated transplants mostly due to the improved resolution of HLA (human leukocyte antigen) typing and the new methods for GvHD prevention. The use of post-transplant cyclophosphamide (PTCY) to mitigate the bidirectional alloreactivity in the setting of haploidentical transplant have revolutionized and revived the field. Based on the promising results of PTCY in the haploidentical transplant field many groups used the same strategy in the setting of HLA-matched donors. This review will carefully examine the available data about the use of PTCY in HLA-matched setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Storb R, Pepe M, Deeg HJ, Anasetti C, Appelbaum FR, Bensinger W, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood. 1992;80:560–1.

    Article  CAS  PubMed  Google Scholar 

  2. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880–7.

    Article  CAS  PubMed  Google Scholar 

  3. Bhatia S, Francisco L, Carter A, Sun C-L, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Weisdorf D, Zhang M-J, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 18:1727–33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant T. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med. 1981;304:1529–33.

    Article  CAS  PubMed  Google Scholar 

  6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.

    Article  CAS  PubMed  Google Scholar 

  7. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood. blood-2011-01-332007.

  8. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733–41.

    Article  CAS  PubMed  Google Scholar 

  9. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science . 1988;241:1655–8.

    Article  CAS  PubMed  Google Scholar 

  10. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola A, di Grazia C, et al. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood. 2001;98:3174–5.

    Article  CAS  Google Scholar 

  11. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Coenen JJA, Koenen H, Van Rijssen E, Kasran A, Boon L, Hilbrands LB, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+T cells. Bone marrow Transplant. 2007;39:537–45.

    Article  CAS  PubMed  Google Scholar 

  13. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood . 2001;98:3456–64.

    Article  CAS  PubMed  Google Scholar 

  14. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol.2013;31:1310–6.

    Article  CAS  PubMed  Google Scholar 

  16. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996;195:129–39.

    Article  CAS  PubMed  Google Scholar 

  17. Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683–93.

    Article  CAS  PubMed  Google Scholar 

  18. Nirmul G. Cyclophsphamide-induced immunologic tolerance to skin homografts. Surg Forum. 1971;22:287–8.

    CAS  PubMed  Google Scholar 

  19. Nirmul G, Severin C, Taub RN. Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice. Transplant Proc. 1973;5:675.

  20. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kanakry CG, O’Donnell PV, Furlong T, De Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–702.

    Article  PubMed  Google Scholar 

  23. Finke Jr, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. lancet Oncol. 2009;10:855–64.

    Article  CAS  PubMed  Google Scholar 

  24. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. New Eng J Med. 2012;367:1487–96.

  25. Kanakry CG, Tsai H-L, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;24:3817–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, et al. Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:112–8.

    Article  CAS  PubMed  Google Scholar 

  27. Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20:890–5.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D’Ambrosio L, Vassallo E, et al. Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. Biol Blood Marrow Transplant. 2017;23:459–66.

    Article  CAS  PubMed  Google Scholar 

  30. Greco R, Lorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528–31.

    Article  CAS  PubMed  Google Scholar 

  31. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40.

  32. Holtick U, Chemnitz J-M, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:941–4.

    Article  CAS  PubMed  Google Scholar 

  34. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant. 2015;21:906–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bolanos-Meade J, Reshef R, Fraser R. Novel approaches for graft-versus-host disease (GvHD) prophylaxis: primary results of progress I multicenter trial of matched allogeneic hematopoietic cell transplantation (alloHCT) using reduced intensity conditioning (RIC) BMT CTN 1203. Biol Blood Marrow Transplant. BMT Tandem Meeting; Salt Lake City, UT, 2018.

  36. Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1828–34.

    Article  CAS  PubMed  Google Scholar 

  37. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037–42.

    Article  CAS  PubMed  Google Scholar 

  38. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, et al. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 1 2019;54:601–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Hess BT, Gao F, DiPersio JF, Westervelt P, Vij R, Uy GL, et al. Use of post-transplant cyclophosphamide (PTCy) with mycophenolate mofetil and tacrolimus in HLA matched allogeneic hematopoietic cell transplant is safe and associated with acceptable transplant outcomes. Am Soc Hematology. 2015;126:1950.

    Article  Google Scholar 

  40. George B, Nisham PN, Devasia AJ, Kulkarni U, Korula A, Lakshmi KM, et al. Post-Transplant Cyclophosphamide (PTCY) as Sole GVHD Prophylaxis is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anaemia Using Matched Sibling Donors. Biol Blood Marrow Transplant. 2018;3:494–500.

  41. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2015;122:3316–26.

    Article  CAS  PubMed  Google Scholar 

  42. Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8:131–8.

    Article  CAS  PubMed  Google Scholar 

  43. Luznik L, Fuchs EJ, Chen AR, Kaup M, Bright EC, Bolanos-Meade J, et al. 6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT). Biol Blood Marrow Transplant. 2007;13:4.

    Article  Google Scholar 

  44. Alousi AM, Saliba RM, Chen J, Andersson BS, Khouri I, Qazilbash MH, et al. A matched controlled analysis of post-transplant cyclophosphamide (Cy) versus tacrolimus and mini-dose methotrexate in matched sibling and unrelated donor transplant recipients receiving reduced-intensity conditioning: post-transplant Cy is associated with higher rates of acute GVHD. Am Soc Hematology. 2012;4200–4200.

    Article  Google Scholar 

  45. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:5:211ra157-211ra157.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immun Res. 2010;47:65–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–8.

    Article  PubMed  Google Scholar 

  48. Atkinson K, Horowitz MM, Biggs JC, Gale RP, Rimm AA, Bortin MM. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone marrow Transplant. 1988;3:5–10.

    CAS  PubMed  Google Scholar 

  49. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report. Biol Blood Marrow Transplant. 2006;12:31–47.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Author information

Authors and Affiliations

  1. Department of Adult Hematology & Stem Cell Transplant, King Faisal Hospital & Research Center, Riyadh, KSA, Saudi Arabia

    Riad El Fakih, Shahrukh K. Hashmi & Mahmoud Aljurf

  2. Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Shahrukh K. Hashmi

  3. Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MDACC, Houston, TX, USA

    Stephen O. Ciurea

  4. Department of Oncology Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Leo Luznik

  5. Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK

    Robert Peter Gale

Authors
  1. Riad El Fakih
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahrukh K. Hashmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen O. Ciurea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leo Luznik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mahmoud Aljurf
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RE wrote the first draft. RE and SKH drafted the concept of the paper. All authors contributed substantially to the conception, acquisition, analyses and interpretation of data.

Corresponding authors

Correspondence to Riad El Fakih or Shahrukh K. Hashmi.

Ethics declarations

Conflict of interest

SKH: Honorarium (Mallinkrodt); RPG: part-time employee of Celgene Corp. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Fakih, R., Hashmi, S.K., Ciurea, S.O. et al. Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant 55, 40–47 (2020). https://doi.org/10.1038/s41409-019-0547-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0547-8

This article is cited by

Search

Advanced search

Quick links